Terapi sasar pikeun pengobatan sarkoma
Taya muhrim kanker, teu loba informasi ngeunaan sarcoma. Nyatana, sarcoma mangrupikeun jinis kanker anu sering dipaliré ku jalma. Kanker jenis ieu muncul dina kulit sareng periosteum, sareng éta sami sareng mendakan yén kaayaan parah gancang, munculna obat-obatan anu nargetkeun sarcoma tiasa ngamungkinkeun pasien pikeun ngambekan, tiasa nyaimbangkeun panyakit dina waktos anu pondok, teras. nyegah kaayaan serius tina metastasis, ngurangan résiko hirup-ngancam ka penderita.
Ubar sasaran pikeun sarcoma
Bevacizumab, pazopanib, sunitinib, jeung sajabana mangrupakeun ubar sarcoma-targeting, tapi ieu teu cocog pikeun unggal sabar. Prasyarat pikeun ngalakukeun tés genetik. Upami mutasi gen mutasi KRAS, tiasa dianggo inhibitor MEK, upami mutasi PIK3CA, BKM120, inhibitor mTOR, jsb. Upami mutasi EGFR, obat TKi tiasa dianggo. Ubar anu ditargetkeun masih gaduh ide, tapi koncina nyaéta terang naon mutasi genetik, anu peryogi bantosan téknologi urutan generasi kadua sabab frékuénsi mutasi genetik dina KRAS, PIK3CA, EGFR sareng MET henteu nambahan dugi ka 100% . Upami kaayaan ngamungkinkeun, AVASTIN ogé tiasa dianggo digabungkeun sareng kémoterapi.
Naon ubar sarcoma-targeting?
1. Bevacizumab
Bevacizumab, a human recombinant VEGF antibody, has been shown to have clinical efficacy in combination regimens in rectal cancer and other malignancies. Agulnik et al. Conducted a multi-center prospective, phase II clinical trial to evaluate the safety and effectiveness of the single-agent bevacizumab, including 30 patients with advanced STS, including 23 cases of angiosarcoma and 7 cases of epithelioid hemangioendothelioma. Monotherapy was well tolerated, partial response (PR), 2 cases, stable disease (SD), 15 cases. After two cycles of treatment, the median progression-free survival (PFS) was 12 weeks, and the overall survival (OS) was 52.7 weeks. This test shows that bevacizumab is safe and effective in patients with angiosarcoma and epithelioid hemangioendothelioma.
2. Pazopanib
Pazopanib mangrupikeun sambetan réséptor molekul leutik tirosin kinase lisan multi-sasaran, sareng mangrupikeun ubar sasaran anu munggaran disatujuan ku FDA salami sababaraha dekade pikeun ngubaran sarcoma jaringan lemes canggih (non-liposarcoma). Pazopanib mangrupikeun reséptor faktor pertumbuhan endothelial vaskular VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α sareng -β, FGFR-1 sareng -3, reséptor sitokin (Kit), reséptor interleukin-2 A reséptor tirosin kinase inhibitor anu bisa ngainduksi T-sél kinase (Itk), leukosit-spésifik protéin tirosin kinase (Lck), jeung transmembran glikoprotein reséptor tirosin kinase (c-Fms). FDA approves pazopanib pikeun penderita sarcoma canggih.
3. Sunitinib
Sunitinib is an oral small molecule receptor tyrosine kinase inhibitor with multiple effects of inhibiting tumor angiogenesis and anti-tumor cell growth. Targets for the drug to exert anti-cancer effects include: PDGFR-α and -β, VEGFR1, VEGFR2, VEGFR3, FLT-3, CSF-1R, kit and ret. Sunitide has multiple effector pathways, making it a reliable anti-tumor targeted drug for non-GIST sarcomas, with two phase II clinical trials evaluating its safety and effectiveness.
4. Sorafinib
Sorafenib mangrupikeun inhibitor multikinase lisan. Éta sakaligus tiasa ngahambat rupa-rupa kinase permukaan intrasélular sareng sél, kalebet kinase BRAF, VEGFR-2, VEGFR-3, PDGFR-β, KIT, sareng FMS-like tyrosine kinase 3 (FLT-3).
5.Cédiranib
Sildenib, faktor pertumbuhan endothelial pan-vascular reséptor tirosin kinase inhibitor, Kummar et al. Kapanggih ngaliwatan ulikan klinis fase II éta némbongkeun efficacy alus pikeun métastatik acinar sarcoma jaringan lemes, 35% Pasén kahontal PR, SD lumangsung dina 60% pasien, sarta laju kontrol kasakit sakabéh ngahontal 84% dina 24 minggu.
6. Anlotinib
Anlotinib mangrupikeun inhibitor reséptor tirosin kinase (RTK) multi-target anu nargétkeun reséptor faktor pertumbuhan endothelial vaskular (VEGFR1 / 2/3) sareng reséptor faktor pertumbuhan fibroblast (FGFR1 / 2/3) Target sapertos reséptor faktor pertumbuhan turunan trombosit (PDGFRα). / β), c-Kit, sareng Ret. Dina taun-taun ayeuna, panilitian ngeunaan panggunaanana dina terapi sasaran tumor diteruskeun.
